参考文献/References:
[1] Bauer KR,Brown M,Cress RD,et al.Descriptive analysis of estro-gen receptor (ER)-negative,progesterone receptor (PR)-negative,and HER2-negative invasive breast cancer,the so-called triple-negative phenotype:a population-based study from the California cancer Registry[J].Cancer,2007,109(9):1721-1728.
[2] Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J].J Clin Oncol,2008,26(8):1275-1281.
[3] Bernsdorf M,Ingvar C,J?rgensen L,et al.Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial[J].Breast Cancer Res Treat,2011,126(2):463-470.
[4] Iwata H,Sato N,Masuda N,et al.Docetaxel followed by fluo-rouracil/epirubicin/cyclophosphamide as neoadjuvant chemothera-py for patients with primary breast cancer[J].Jpn J Clin Oncol,2011,41(7):867-875.
[5] J?rg Schwarz-Dose,Michael Untch,Reinhold Tiling,et al.Monitor-ing primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with[18F]fluorodeoxyglucose[J].J clin Oncol,2009,27(4):535-541.
[6] Early Breast Cancer Trialists’Collaborative Group (EBCTCG).Ef-fects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,365(9472):1687-1717.
[7] Sorlie T,Perou CM,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical impli-cations[J].Proc Natl Acad Sci U S A,2001,98(19):10869-10874.
[8] Nielsen TO,Hsu FD,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367-5374.
[9] Bertucci F,Finetti P,Cervera N,et al.How basal are triple-negative breast cancers?[J].Int J Cancer,2008,123(1):236-240.
[10] Nofech-Mozes S,Trudeau M,Kahn HK,et al.Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast can-cers[J].Breast Cancer Res Treat,2009,118(1):131-137.
[11] Carey LA,Perou CM,Livasy CA,et al.Race,breast cancer sub-types,and survival in the Carolina Breast Cancer Study[J].JAMA,2006,295(21):2492-2502.
[12] de Ruijter TC,Veeck J,de Hoon JP,et al.Characteristics of triple-negative breast cancer[J].J Cancer Res Clin Oncol,2011,137(2):183-192.
[13] Rhee J,Han SW,Oh DY,et al.The clinicopathologic characteris-tics and prognostic significance of triple-negativity in node-negative breast cancer[J].BMC Cancer,2008,8:307.
[14] Parikh RR,Housman D,Yang Q,et al.Prognostic value of triple-negative phenotype at the time of locally recurrent,conservatively treated breast cancer[J].Int J Radiat Oncol Biol Phys,2008,72(4):1056-1063.
[15] Samphao S,Eremin JM,El-Sheemy M,et al.Treatment of estab-lished breast cancer in post-menopausal women:role of aromatase inhibitors[J].Surgeon,2009,7(1):42-55.
[16] Pienkowski T,Zielinski CC.Trastuzumab treatment in patients with breast cancer and metastatic CNS disease[J].Ann Oncol,2010,21(5):917-924.
[17] Wang S,Yang H,Tong F,et al.Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast can-cer[J].Gan To Kagaku Ryoho,2009,36(2):255-258.
[18] Esserman LJ,Perou C,Cheang M,et al.Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and pacli-taxel:The I-SPY TRIAL (CALGB 150007/150012,ACRIN6657)[J/OL].J Clin Oncol,2009,27(Suppl 18s):LBA515[2013-06-07].http://meetinglibrary.asco.org/content/35410-65.
[19] Liedtke C,Mazouni C,Hess KR,et al.Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer[J].J Clin Oncol,2008,26(8):1275-1281.
[20] Zhang C,Yan SX,Crockford S,et al.Triple-negative breast cancer is associated with higher rate of locoregional recurrence for patient achieving less than a pCR following neoadjuvant chemotherapy,surgery,and radiation therapy[J].Inter Radiat Oncol,2013,87(2):S99.
[21] Guarneri V,Broglio K,Kau SW,et al.Prognostic value of patholog-ic complete response after primary chemotherapy in relation to hor-mone receptor status and other factors[J].J Clin Oncol,2006,24(7):1037-1044.
[22] De Laurentiis M,Cianniellob D,Caputob R,et al.Treatment of triple-negative breast cancer (TNBC):current options and future perspectives[J].Cancer Treat Rev,2010,36 Suppl 3:S80-86.
[23] Lehmann BD,Bauer JA,Chen X,et al.Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J].J Clin Invest,2011,121:2750-2767.
[24] Masuda H,Baggerly KA,Wang Y,et al.Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J].Clin Cancer Res,2013,19(19):5533-5540.
[25] Berriolo-Riedinger A,Touzery C,Riedinger JM,et al.[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy[J].Eur J Nucl Med Mol Imaging,2007,34(12):1915-1924.
[26] Schwarz-Dose J,Untch M,Tiling R,et al.Monitoring primary sys-temic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with[18F]fluo-rodeoxyglucose[J].J Clin Oncol,2009,27(4):535-541.
[27] Groheux D,Giacchetti S,Espie’M,et al.Early monitoring of re-sponse to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT:defining a clinical aim[J].Eur J Nucl Med Mol Imaging,2011,38(3):419-425.
[28] McDermott GM,Welch A,Staff RT,et al.Monitoring primary breast cancer throughout chemotherapy using FDG-PET[J].Breast Cancer Res Treat,2007,102(1):75-84.
[29] Basu S,Chen W,Tchou J,et al.Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluo-rodeoxyglucose/positron emission tomography imaging parameters[J].Cancer,2008,112(5):995-1000.
[30] Tchou J,Sonnad SS,Bergey MR,et al.Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer[J].Mol Imaging Biol,2010,12(6):657-662.
[31] Koolen BB,Pengel KE,Wesseling J,et al.FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative,but not in HER2-positive breast cancer[J].Breast,2013,22(5):691-697.
[32] Humbert O,Berriolo-Riedinger A,Riedinger JM,et al.Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer:influence of tumor subtypes[J].Ann Oncol,2012,23(10):2572-2577.
[33] Groheux D,Hindie E,Giacchetti S,et al.Triple-negative breast cancer:early assessment with 18F-FDG PET/CT during neoadju-vant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse[J].J Nucl Med,2012,53(2):249-254.
[34] Groheux D,Espié M,Giacchetti S,et al.Performance of FDG PET/CT in the clinical management of breast cancer[J].Radiology,2013,266(2):388-405.
[35] Rousseau C,Devillers A,Sagan C,et al.Monitoring of early re-sponse to neoadjuvant chemotherapy in stage II and III breast can-cer by[18F]fluorodeoxyglucose positron emission tomography[J].J Clin Oncol,2006,24(34):5366-5372.
[36] Schelling M,Avril N,Nahrig J,et al.Positron emission tomography using[18F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer[J].J Clin Oncol,2000,18(8):1689-1695.
相似文献/References:
[1]何燕,苏晋,郑晓霞,等.P-糖蛋白抑制剂在PET显像中的应用研究[J].国际放射医学核医学杂志,2016,40(1):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
He Yan,Su Jin,ZhengXiaoxia,et al.Developing P-glycoprotein inhibitor marked by PET[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):1.[doi:10.3760/cma.j.issn.1673-4114.2016.01.001]
[2]许飞,刘建军,黄钢,等.PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展[J].国际放射医学核医学杂志,2016,40(1):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
Xu Fei,Liu Jianjun,Huang Gang,et al.The application of hypoxia imaging with PET in predicting tumor hypoxia and guiding clinical therapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):35.[doi:10.3760/cma.j.issn.1673-4114.2016.01.008]
[3]胡伟,赵军.小胶质细胞在AD炎性机制中的作用及其常见PET显像剂的应用进展[J].国际放射医学核医学杂志,2016,40(1):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
Hu Wei,Zhao Jun.Microglia’s Alzheimer disease inflammatory mechanisms and progress of its common application in PET imaging agents[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):44.[doi:10.3760/cma.j.issn.1673-4114.2016.01.009]
[4]张莹莹,王振光,孔艳.PET/CT显像在肺间质纤维化中的应用进展[J].国际放射医学核医学杂志,2016,40(1):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
Zhang Yingying,Wang Zhenguang,Kong Yan.Application advancement on PET/CT in pulmonary interstitial fibrosis[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):55.[doi:10.3760/cma.j.issn.1673-4114.2016.01.011]
[5]李海峰,张晓军,李云钢,等.国产模块LOOP环改良法合成11C-蛋氨酸[J].国际放射医学核医学杂志,2016,40(2):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
Li Haifeng,Zhang Xiaojun,Li Yungang,et al.Synthesis of 11C-methionine on home-made module by the improved LOOP method[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):106.[doi:10.3760/cma.j.issn.1673-4114.2016.02.004]
[6]杨雷,袁卫红,王家平,等.99Tcm-MIBI显像与钼靶X线对乳腺癌诊断的比较研究[J].国际放射医学核医学杂志,2016,40(2):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
Yang Lei,Yuan Weihong,Wang Jiaping,et al.Diagnostic value of technetium 99Tcm sestamibi and X-ray mammography in breast cancer: a comparison study[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):111.[doi:10.3760/cma.j.issn.1673-4114.2016.02.005]
[7]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[8]马乐,张万春,李晓敏.乳腺癌前哨淋巴结核素显像新进展[J].国际放射医学核医学杂志,2016,40(2):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
Ma Le,Zhang Wanchun,Li Xiaomin.Evolution of radionuclide imaging of sentinel node lymphscintigraphy in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):145.[doi:10.3760/cma.j.issn.1673-4114.2016.02.012]
[9]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[10]尤阳,轩昂,张杰,等.淋巴瘤患者大脑静息葡萄糖代谢改变[J].国际放射医学核医学杂志,2016,40(4):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
You Yang,Xuan Ang,Zhang Jie,et al.Changes in resting-state brain glucose metabolism in patients with lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):255.[doi:10.3760/cma.j.issn.1673-4114.2016.04.003]
[11]胡鸿,唐刚华,聂大红.乳腺癌分子显像研究进展[J].国际放射医学核医学杂志,2015,39(1):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
Hu Hong,Tang Ganghua,Nie Dahong.Progress on molecular imaging of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):91.[doi:10.3760/cma.j.issn.1673-4114.2015.01.019]
[12]胡梦裳,章斌.PET/CT显像在乳腺癌疗效评价及预后中的作用[J].国际放射医学核医学杂志,2014,38(5):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
Hu Meng-shang,Zhang Bin.The role of PET/CT imaging in the evaluation of the efficacy and prognosis of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):332.[doi:10.3760/cma.j.issn.1673-4114.2014.05.013]
[13]董佳佳,章斌.多种影像学方法评价乳腺癌新辅助化疗疗效的价值比较[J].国际放射医学核医学杂志,2014,38(6):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
Dong Jia-jia,Zhang Bin.Comparision on the values of different image modalities in monitoring the response to neoadjuvant chemotherapy in breast cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):427.[doi:10.3760/cma.j.issn.1673-4114.2014.06.018]
[14]袁建伟,杨劼,贺小红,等.乳腺癌18F-FDG PET/CT和3.0T MRI联合显像评分与Ki-67表达水平的相关性分析[J].国际放射医学核医学杂志,2013,37(2):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Correlation between combined imaging modalities of 18F-FDG PET/CT and 3.0T MRI and expression of Ki-67 in breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):84.[doi:10.3760/cma.j.issn.1673-4114.2013.02.006]
[15]袁建伟,杨劼,贺小红,等.18F-FDG PET/CT与3.0T MRI联合显像在乳腺癌原发病灶诊断中的价值[J].国际放射医学核医学杂志,2013,37(4):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
YUAN Jian-wei,YANG Jie,HE Xiao-hong,et al.Diagnosis value of 18F-FDG PET/CT and 3.0T MRI combined imaging in detecting the primary focus of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):199.[doi:10.3760/cma.j.issn.1673-4114.2013.04.003]
[16]林美福,陈文新,周硕,等.18F-FES PET/CT显像在雌激素受体阳性乳腺癌诊疗中的初步应用[J].国际放射医学核医学杂志,2013,37(4):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
LIN Mei-fu,CHEN Wen-xin,ZHOU Shuo,et al.Application of 18F-FES PET/CT in diagnosis and endocrine therapy of patients with estrogen receptorpositive breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):216.[doi:10.3760/cma.j.issn.1673-4114.2013.04.007]
[17]夏晓天,张永学.影像学检查在乳腺癌的诊断及疗效评估中的应用价值[J].国际放射医学核医学杂志,2010,34(4):242.[doi:10.3760/cma.j.issn.1673-4114.2010.04.014]
XIA Xiao-tian,ZHANG Yong-xue.The value of imaging examinations in diagnosis and curative effect evaluation of breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):242.[doi:10.3760/cma.j.issn.1673-4114.2010.04.014]
[18]鲁胜男,冯彦林.乳腺癌新辅助化疗过程中18F-FDG PET-CT与化疗前Ki-67、COX-2表达的相关性研究[J].国际放射医学核医学杂志,2011,35(4):238.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
LU Sheng-nan,FENG Yan-lin.The correlation analysis between 18F-FDG PET-CT in breast cancer with neoadjuvant chemotherapy and the expression of Ki-67 and COX-2 before neoadjuvant chemotherapy[J].International Journal of Radiation Medicine and Nuclear Medicine,2011,35(3):238.[doi:10.3760/cma.j.issn.1673-4114.2011.04.011]
[19]张亶,章斌,邓胜明,等.18F-FDG PET/CT在乳腺癌术后随访中的价值[J].国际放射医学核医学杂志,2017,41(3):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]
Zhang Dan,Zhang Bin,Deng Shengming,et al.Clinical value of 18F-FDG PET/CT in follow-up of postoperative breast cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):159.[doi:10.3760/cma.j.issn.1673-4114.2017.03.001]